A pharmaceutical company is making a $100 EpiPen because it’s the right thing to do

RX Company and EpiPen Savings

Mark Baum is the CEO of Imprimis Pharmaceuticals and in many ways a true American hero.

Remember when Martin Shkreli raised the cost of a life-saving AIDS drug by 5000%? It was Baum and his Imprimis Pharmaceuticals who swooped in to offer a $1 alternative.

This time, Baum is back at it, promising to deliver a $100 EpiPen by the end of the year.

The move arrives after America’s newest villain, Mylan CEO Heather Bresch, raised the cost of the EpiPen to more than $500.

Baum has called those price hikes “shameful” and said his company’s new compound will be ready by the end of the year.

“I don’t need to make $19 million a year,” Baum said, referring to the big pay package Mylan’s CEO Heather Bresch took home last year.

“Tonight when I go home I’m going to eat a nice piece of fish and the fish I eat isn’t any better or worse than what she is going to eat.”

He’s pretty much the Superman of the pharma world right now, swooping in to save lives with lower prices while defeating the evil Heather Bresch’s and Martin Shkreli’s of the world.